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Edited by Berend WieringaAbstract Tenascin-X is an extracellular matrix protein whose
absence leads to an Ehlers-Danlos syndrome in humans, charac-
terized mainly by disorganisation of collagen and elastic ﬁbril
networks. After producing recombinant full-length tenascin-X
in mammalian cells, we ﬁnd that this protein assembled into
disulﬁde-linked oligomers. Trimers were the predominant form
observed using rotary shadowing. By solid phase interaction
studies, we demonstrate that tenascin-X interacts with types I,
III and V ﬁbrillar collagen molecules when they are in native
conformation. The use of tenascin-X variants with large regions
deleted indicated that both epidermal growth factor repeats and
the ﬁbrinogen-like domain are involved in this interaction. More-
over, we demonstrate that tenascin-X binds to the ﬁbril-associ-
ated types XII and XIV collagens. We thus suggest that
tenascin-X, via trimerization and multiple interactions with com-
ponents of collagenous ﬁbrils, plays a crucial role in the organi-
sation of extracellular matrices.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tenascin-X (TNX) is an extracellular matrix glycoprotein
that belongs to the tenascin family. All tenascins share the
same multidomain structure consisting of an N-terminal re-
gion involved in oligomerization, a series of epidermal growth
factor (EGF)-like repeats, a variable number of ﬁbronectin-
type III (FNIII) modules and a C-terminal domain homolo-
gous to ﬁbrinogen (Fbg). This complex structure gives rise to
multiple interactions with proteins and carbohydrates [1].
Functions of TNX in extracellular matrix network forma-
tion and/or stabilization are suggested by in vivo observations.
Some patients show an Ehlers-Danlos-like syndrome that is
due to TNX deﬁciency [2,3]. Major clinical symptoms consist
of skin hyperextensibility, joint laxity and easy bruising. Ultra-
structural analyses reveal abnormalities in collagen ﬁbril net-
works and elastic ﬁbres [2,4]. Mice deﬁcient in TNX also
exhibit connective tissue defects such as skin hyperextensibil-
ity. Fibroblasts isolated from TNX/ mice failed to deposit
collagen in cell culture [5]. Considering these alterations of
connective tissue structure and the localization of TNX at*Corresponding author. Fax: +33 472 72 26 04.
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doi:10.1016/j.febslet.2006.10.037the surface of collagen ﬁbrils [6], TNX might be involved in
collagen ﬁbrillogenesis and/or in the interaction between colla-
gen ﬁbrils. We have previously shown that TNX interacts with
decorin and suggested that this small proteoglycan may medi-
ate the interaction between TNX and collagen ﬁbrils [7].
The aim of this study was to test ﬁbrillar and ﬁbril-associ-
ated collagens as possible ligands for TNX. To this end, we
produced, in mammalian cells, full length TNX and TNX vari-
ants with large regions deleted. These proteins were used to
test interactions with collagens by solid phase assays. Since
no data were available on the oligomerization of TNX, we also
analyzed the structure of full length TNX by rotary shadow-
ing.2. Materials and methods
2.1. Production of recombinant TNX in mammalian cells
The cDNA clones used in this study (Flex-2, Flex-12, Flex-21,
PCR2, and TX2) originated from our previous work concerning the
full-length sequencing of bovine TNX [8]. The strategy used to make
the diﬀerent construct is shown in Fig. 1. To obtain the four constructs
corresponding to recombinant TNX, the SacI–EcoRI fragment of
cDNA clone TX2 was cloned into pBluescriptSK (Stratagene) (clone
1). The BamHI–EcoRI fragment from clone PCR2 was successively in-
serted into the BamHI and EcoRI sites of clone 1 (clone 2). To obtain
clone 3, the AatII–EcoRI fragment from clone 2 was replaced by a sim-
ilar DNA insert from cDNA clone Flex-21. Clone 4 consists of the
SacI–EcoRI fragment of cDNA clone Flex-12 cloned in pBluscriptSK.
In a next step, the StuI–StuI–EcoRI DNA insert from clone 4 was re-
placed by the StuI–EcoRI fragment from clone Flex-221 (clone 5). To
generate clone 6, the StuI–StuI fragment from clone Flex-12 was
cloned into the unique StuI site of clone 5 in the correct orientation.
The NcoI–EcoRI fragment from clone 6 was inserted into clone 3 to
generate clone 7. To obtain the DNA fragment common to the four
constructs, the NcoI–NcoI fragment from cDNA clone Flex-2 was in-
serted in the right orientation into the NcoI site of clone 7 (clone 8,
nucleotides 2751-10001, GenBank accession number Y11915). The
two 5 0 PCR fragments (P1 and P2) were generated using Taq Expand
and cloned into the SacI fragment of pBluescript. Clones 9 and 10 were
obtained by cloning into the SacI site of clone 8, the SacI fragment of
clones P1 and P2, respectively. The two last RT-PCR products, P3 and
P4 were cloned into the EcoRI–EcoRV sites of clones 9 or 10. The ﬁnal
step consisted of cloning of the four ﬁnal HindIII–EcoRV fragments
into the pSec-TagHygroB vector (Invitrogen). All the PCR fragments
have been sequenced.
Transfection of HEK 293 cells with the four constructions, selection
with hygromycin, cloning and selection of positive cells were carried
out as previously described [9]. For the production of recombinant
proteins, cells were cultured in serum-free conditions and the medium
was collected every 3–4 days. Recombinant proteins were puriﬁed from
the medium by two chromatographic steps. Since we had previously lo-
cated a heparin-binding site within the FNIII domains of TNX [9], the
ﬁrst chromatography was performed on heparin. The media were
loaded on a heparin-Sepharose column (Pharmacia). After rinsing in
PBS, bound proteins were eluted with 0.5 M NaCl in PBS. Fractionsblished by Elsevier B.V. All rights reserved.
Fig. 1. Recombinant TNX variants produced in HEK293 cells. (A)
cDNA fragments (clones 1–10) and PCR products (P1–P4) used for
the generation of TNX expression constructs are represented above a
schematic drawing of recombinant TNX. rTNX corresponds to the full
length TNX, comprising the N-terminal oligomerization region (N-
term. (olig.)), 14.5 EGF repeats, 30 FNIII modules and the C-terminal
Fbg domain. rTNXDE is deleted from the EGF-like domains,
rTNXDF is deleted from the Fbg-like domain, and rTNXDEDF
comprises only the FNIII modules. According to bovine TNX protein
(accession number CAA72671), rTNX, rTNXDE, rTNXDF and
rTNXDEDF included residues 23-4135, 745-4135, 23-3910 and 745-
3910 respectively. Ev, EcoRV; H3, HindIII. (B) SDS–PAGE migration
proﬁles under reducing conditions of recombinant TNX molecules
after the two puriﬁcation steps. Lane 1: rTNX, lane 2: rTNXDF, lane
3: rTNXDE, lane 4: rTNXDEDF. The position of molecular mass
standards is shown at the left of the gel.
Fig. 2. Puriﬁcation and rotary shadowing of rTNX. (A) Comparison
of SDS–PAGE migration proﬁles of puriﬁed rTNX in the presence (+)
or absence () of dithiothreitol (DTT). Migration of protein standards
is shown at the left of the upper panel. (B) Rotary shadowing
micrographs of puriﬁed rTNX molecules appearing as trimers
(bar = 50 nm).
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Tris–HCl, pH 8.0. A second chromatography step was performed on
Q-Sepharose (Pharmacia) and elution was achieved by a linear gradi-
ent of NaCl in 50 mM Tris–HCl, pH 8.0. Puriﬁed proteins were dia-
lyzed against PBS and stored at 80 C. Protein concentration was
determined using the QuantiPro BCA assay kit (Sigma). Electrophore-
sis was carried out in 6% acrylamide gels in the presence of sodium
dodecyl sulfate (SDS–PAGE) and gels were stained with Coomassie
blue.2.2. Solid phase assays
Ninety-six well microtiter plates (Maxisorp, Nunc) were coated
overnight at +4 C with collagens diluted in water. Acid-soluble bovine
collagen, mainly consisting of type I collagen was from Coletica (Lyon,
France), and types III and V collagens are a generous gift of Dr. M.C.
Ronzie`re (IBCP, Lyon, France). Types XII and XIV collagens were
prepared using previously described procedures [10,11]. In some
assays, collagen was denaturated by heating the solution for 20 min
at 95 C before being added to the wells. All further steps were done
at room temperature. Wells were saturated with T-PBS-BSA (Tween
0.05%, bovine serum albumin 1% in phosphate buﬀered saline) for
2 h and then incubated with puriﬁed recombinant TNX diluted in
the same buﬀer for a further 2 h. Wells were rinsed with T-PBS (Tween
0.05% in phosphate buﬀered saline), incubated for 1 h with an anti-
body speciﬁc for TNX diluted in T-PBS-BSA (mouse monoclonal
clone 8F2 [9], hybridoma supernatant, diluted 1/80, or guinea pig poly-
clonal serum obtained by immunization with the recombinant Fbg
domain, diluted 1/500). Bound antibodies were further revealed with
anti-mouse IgG (BioRad) or with anti-guinea pig IgG (Jackson Labo-
ratories) conjugated to peroxidase for 30 min. After a last series of
rinses, bound peroxidase was detected with H2O2 and 2,2-azino-
bis(3-ethylbenthiazoline-6-sulfonic acid) and the absorbance read at
405 nm. Each data point are the means of triplicate determinations
and bars represent the standard error of the mean.2.3. Rotary shadowing
The TNX solution was dialyzed against 0.2 M ammonium bicarbon-
ate, diluted with glycerol (v/v), and spread on ﬂeshly cleaved mica
sheets. Samples were shadowed in a Balzers MED10 coating unit
and the replicas were observed with a Philips CM120 microscope at
the ’’Centre de Technologie des Microstructures’’ (Universite´ de
Lyon).
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3.1. Production and characterization of recombinant TNX
In order to study the interaction between TNX and ﬁbrillar
collagens, we decided to produce recombinant TNX as a full-
length molecule and as variants with large regions deleted. The
diﬀerent proteins are shown in Fig. 1A. The yield was 3 mg of
puriﬁed protein per litre of culture medium for rTNX and de-
leted variants exhibited variable production eﬃciencies com-
prised between 1 and 30 mg of protein per litre. As shown in
Fig. 1B, the proteins puriﬁed by the two chromatographic
steps appeared homogenous and as a single band compatible
with their respective molecular mass. As no data were available
on the oligomerization properties of TNX, we compared the
migration proﬁles of rTNX under reducing and non-reducing
conditions. Distinct patterns were observed, i.e. the appear-
ance of a single band of high molecular mass located at the
upper limit of the separating gel under non-reducing condi-
tions (Fig. 2A). This result indicated that rTNX was produced
as disulﬁde-linked oligomers. In the preparation of full-length
TNX submitted to rotary shadowing, the majority of mole-
cules appeared as trimers (Fig. 2B). On each arm, we could ob-
serve one terminal globule, a thick ﬂexible region, a thinner
short segment and the three arms associated by another glob-
ular domain. As shown in the early studies concerning tenas-
cin-C [12,13], these successive domains may respectivelyconc. (nM)
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Fig. 3. Solid-phase assay of the interaction between rTNX and ﬁbrillar (A) a
5 lg/mL and interactions were measured with variable concentrations of solcorrespond to the C-terminal Fbg, the FNIII and the EGF re-
peats, and the N-terminal oligomerization region. In tenascin-
C, which is secreted as hexamers, the oligomerization process
has been studied in detail. The ﬁrst step involves the nucleation
of three chains in the region of the heptad repeats. The trimer
is stabilized by disulﬁde intermolecular bonds at the margin of
the heptad region. These heptads are common motives found
in several extracellular matrix proteins such as laminins,
thrombospondins and tenascins [14]. The second step of tenas-
cin-C assembly involves the most N-terminal region and cys-
teine 64, responsible for the association of two trimers to
form a hexamer [15,16]. The trimeric association of TNX
might be explained by a structure of its amino-terminal region
diﬀering from that of tenascin-C. Hence, the most amino-ter-
minal 20 residues and the equivalent of cysteine 64 are absent
in TNX [8,17]. In previous studies, we found that TNX ex-
tracted from tissues appeared mainly monomeric [6,8], suggest-
ing that, during the puriﬁcation process, the heptad-containing
region was submitted to partial proteolysis. These rotary shad-
owing studies of recombinant TNX also showed the eﬃcacy of
the system for producing intact correctly folded proteins
usable for functional studies.
3.2. Interaction with collagens
The interaction of TNX with collagen was tested by solid-
phase interaction assays. Fibrillar collagen molecules werecoll. I
coll. III
coll. V
coll. I denat.
50 60
0 80
coll. XII
coll. XIV
FN
nd ﬁbril-associated (B) collagens. Wells were coated with collagens at
uble TNX.
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and the recombinant TNX was added and revealed by one
monoclonal antibody whose epitope is located within the
FNIII domains. The results are shown in Fig. 3A. Full-length
rTNX interacted with collagen types I, III and V in their native
state, the best interaction being obtained with collagen V. Heat
denaturation of collagens before coating led to the complete
abolition of the interaction with rTNX, either with collagen
I (Fig. 3A) or with collagens III and V (data not shown).
The triplehelical structure of collagen monomers is thus crucial
for the interaction with TNX. Other components of the collag-
enous ﬁbril environment, i.e. ﬁbril-associated collagens XII
and XIV, were also shown to interact with TNX, whereas
ﬁbronectin was ineﬀective in this assay (Fig. 3B). Finally, de-
leted variants were used to map the collagen-binding site on
the TNX molecule. As shown in Fig. 4, deletion of the Fbg do-
main or the region comprising the EGF-like modules led to a
strong decrease in the interaction with ﬁbrillar collagen I.
Moreover, when the Fbg domain alone was used, no interac-
tion is observed. These observations suggest that the EGF re-
gion, and one site including the Fbg domain, co-operate in the
interaction with ﬁbrillar collagens. This result is diﬀerent from
that of Minamitani et al., who found an interaction with mu-
tants deleted from these domains [18]. This diﬀerence may be
due to the recombinant TNX produced, since they used a short
form comprising only 24 FNIII domains, compared with our
long form encompassing 30 of these modules. Also, the design
of their experiment is diﬀerent since they coated recombinant
TNX and added collagen type I diluted in PBS. Under these
conditions, collagen might form aggregates that have proper-
ties diﬀerent from monomeric collagen. However, our results
are in accordance with the study by these authors who
observed that these two regions, namely Fbg domain and
EGF-like modules, were involved in the acceleration of
in vitro collagen ﬁbrillogenesis induced by TNX [18]. More-
over, we could exclude the possibility that the trimerization
of TNX was important for this interaction because when we0 20 40 60 80 100
rTNX
rTNXΔE
rTNXΔEΔF
rF
rTNXΔF
Fig. 4. Mapping of regions involved in the interaction between TNX
and type I collagen. Wells were coated with 5 lg/mL of acid-soluble
bovine type I collagen. rTNX and its variants were added at a 80 nM
concentration. For rTNXDF, rTNXDE and rTNXDEDF, detection
was with the monoclonal antibody 8F2 that is speciﬁc for the tenth
FNIII domain of TNX. For rF, detection was with an anti-guinea pig
serum obtained by immunization with recombinant Fbg domain.
Results are given as a percentage of the absorbance measured for the
full length rTNX revealed by the same antibody.used monomeric TNX extracted from tissues, an interaction
similar to that observed with rTNX was obtained (unpublished
data).
3.3. Conclusions
Several studies suggest that TNX acts as a bridge between
collagen ﬁbrils. Firstly, we have demonstrated that TNX is lo-
cated between ﬁbrils when they are organized in bundles [6],
and secondly, Bristow et al. have shown that, in the skin of
a patient deﬁcient in TNX, the interﬁbrillar distance is in-
creased [19]. As demonstrated here, ﬁbrillar types I, III, V
and ﬁbril-associated XII and XIV collagens, are partners of
TNX, and in a previous paper, we have shown that TNX inter-
acts with decorin, a small proteoglycan located on collagen ﬁ-
brils [7]. Thus, the bridging property of TNX might originate
from its multiple interactions with components of the ﬁbrillar
surface. Moreover, TNX is secreted as disulﬁde-linked trimers,
a property that is probably important for bridging. Finally, the
FNIII domains of TNX might be important in relation to elas-
tic properties of the molecule. It has been demonstrated that
these domains are able to partially unfold under stretching
conditions and recover their native conformation with relaxa-
tion [20]. Consequently, TNX might be important for the com-
pliance of connective tissues. In conclusion, our results
reinforce the concept that TNX, by trimerization and interac-
tions with multiple components of the collagenous ﬁbrils, plays
a central role in the organisation of connective tissues. It re-
mains to be determined if and how these interactions are in-
volved in the in vivo deposition of collagen networks.
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